Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation

Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation

Background Osimertinib is the most promising treatment option for patients with epidermal growth factor receptor (EGFR) mutation‐positive non‐small cell lung cancer (NSCLC) with acquired T790M resistance. However, recent studies have suggested that osimertinib could increase the frequency of serious...

Full description

Bibliographic Details
Main Authors: Ou Yamaguchi, Kyoichi Kaira, Tomonori Kawasaki, Atsuto Mouri, Kosuke Hashimoto, Ayako Shiono, Shun Shinomiya, Yu Miura, Fuyumi Nishihara, Yoshitake Murayama, Kunihiko Kobayashi, Satoshi Mochida, Hiroshi Kagamu
Format: Article
Language:English
Published: Wiley 2020-04-01
Series:Thoracic Cancer
Subjects:
Hepatotoxicity
immune checkpoint inhibitor
nivolumab
non‐small‐cell lung cancer
osimertinib
Online Access:https://doi.org/10.1111/1759-7714.13363

Internet

https://doi.org/10.1111/1759-7714.13363

Similar Items